Cumberland Pharmaceuticals

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose (lactulose) for Oral Solution, a prescription laxative, Vaprisol (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak for the treatment of H. pylori and duodenal ulcer disease, and Ethyol (amifostine) for Injection, for the treatment of oncology patients. The Company also owns rights to ifetroban and are developing Hepatoren (ifetroban) Injection for the treatment of Hepatorenal Syndrome, Boxaban (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, VasculanTM (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban, for the treatment of portal hypertension.

Company Growth (employees)
Type
Public
HQ
Nashville, US
Founded
1999
Size (employees)
82 (est)
Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, US

Cumberland Pharmaceuticals Office Locations

Cumberland Pharmaceuticals has an office in Nashville
Nashville, US (HQ)
950 2525 West End Ave

Cumberland Pharmaceuticals Data and Metrics

Cumberland Pharmaceuticals Financial Metrics

Cumberland Pharmaceuticals's revenue was reported to be $9.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

9.6 m

Gross profit (Q1, 2017)

8.3 m

Gross profit margin (Q1, 2017), %

86%

Net income (Q1, 2017)

(1.3 m)

EBIT (Q1, 2017)

(657.8 k)

Market capitalization (15-Aug-2017)

105.5 m

Cash (31-Mar-2017)

35 m
Cumberland Pharmaceuticals's current market capitalization is $105.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

32 m36.9 m33.5 m33 m

Revenue growth, %

15%(9%)(1%)

Cost of goods sold

5.4 m5.1 m5 m6 m

Gross profit

26.6 m31.8 m28.6 m27.1 m

Gross profit Margin, %

83%86%85%82%

Sales and marketing expense

14.4 m14.9 m

R&D expense

5.6 m3.4 m

General and administrative expense

9.5 m8.4 m

Operating expense total

35.8 m33.3 m32.4 m34.5 m

EBIT

(3.8 m)3.6 m1.1 m(1.4 m)

EBIT margin, %

(12%)10%3%(4%)

Interest expense

103.4 k67.1 k73.9 k106.4 k

Interest income

230.3 k251.4 k209.2 k204.7 k

Pre tax profit

(3.7 m)3.7 m1.2 m(1.3 m)

Income tax expense

(1.5 m)1.4 m(575.8 k)330.9 k

Net Income

(2.2 m)2.4 m671.1 k(1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

9.8 m9.7 m8.7 m8.9 m7.9 m7.7 m7.4 m8.8 m9.6 m

Cost of goods sold

1.3 m1.3 m1.2 m1.2 m980.2 k1.2 m1.2 m2 m1.4 m

Gross profit

8.5 m8.4 m7.5 m7.7 m6.9 m6.5 m6.3 m6.8 m8.3 m

Gross profit Margin, %

87%86%87%86%88%84%84%78%86%

R&D expense

861.2 k934.8 k1.9 m828.1 k757.4 k706.5 k678.8 k644.7 k898.4 k

General and administrative expense

2.1 m2.2 m1.6 m2.2 m1.8 m2.1 m1.9 m1.9 m2.1 m

Operating expense total

3 m3.1 m3.5 m3 m2.6 m2.8 m2.6 m2.5 m3 m

EBIT

1.2 m989 k4.1 k673.9 k270.9 k(500.6 k)(105.3 k)130.1 k(657.8 k)

EBIT margin, %

12%10%0%8%3%(6%)(1%)1%(7%)

Interest expense

(12.3 k)(26.9 k)(15.6 k)(18.5 k)(19.8 k)(20.4 k)(28.2 k)(29.1 k)(31.7 k)

Interest income

29.5 k108 k56.4 k57.8 k64.1 k77.1 k31.5 k51.6 k52.5 k

Pre tax profit

1.2 m1.1 m45 k713.3 k315.1 k(443.9 k)(102.1 k)152.7 k(637 k)

Income tax expense

(523.3 k)(341 k)(18.5 k)(319 k)(193.4 k)175.3 k41.1 k(57.2 k)(656.6 k)

Net Income

709.5 k729.2 k26.5 k394.3 k121.7 k(268.6 k)(60.9 k)95.5 k(1.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

40.9 m39.9 m38.2 m34.5 m

Inventories

5.7 m5.6 m4.3 m5.4 m

Current Assets

68.7 m70.8 m67.1 m65.5 m

PP&E

880.6 k651 k536.5 k464.5 k

Total Assets

87.6 m95.4 m91.9 m93.4 m

Accounts Payable

2 m3.2 m2.9 m8 m

Current Liabilities

7.5 m13.7 m12.4 m14.8 m

Total Liabilities

20.3 m

Retained Earnings

16.4 m18.8 m19.5 m18.6 m

Total Equity

79.3 m80.8 m76.8 m73.1 m

Financial Leverage

1.1 x1.2 x1.2 x1.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

39.1 m39.6 m39 m38.9 m38.3 m36.4 m35.8 m35.5 m35 m

Inventories

7 m6.1 m4.6 m4.8 m4.2 m4.1 m4.9 m5 m5.6 m

Current Assets

70.6 m70.1 m67.5 m68.2 m67.7 m64.9 m64 m67 m63.5 m

PP&E

726.9 k731.1 k685.2 k568.8 k541.8 k558.2 k505.7 k482.6 k538.4 k

Total Assets

93.5 m93.9 m92.2 m92.9 m92.1 m89.2 m87.9 m91.1 m91.9 m

Accounts Payable

4.2 m3.2 m3.4 m4.1 m4.1 m4.1 m3.7 m6.7 m7.3 m

Current Liabilities

11.9 m12.2 m11.9 m11.5 m11.9 m11.1 m8.9 m11.7 m14.1 m

Retained Earnings

17.4 m18.1 m18.9 m19.3 m19.4 m19.3 m19.2 m19.4 m18.4 m

Total Equity

80.7 m80.9 m79.3 m78.7 m77.5 m75.3 m74.4 m74.4 m72.2 m

Financial Leverage

1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x1.2 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(2.2 m)2.4 m671.1 k(1 m)

Depreciation and Amortization

1.3 m2 m2.2 m2.4 m

Accounts Receivable

1.5 m(974.3 k)(572.4 k)(1.3 m)

Inventories

495.5 k1.5 m1.3 m(1.1 m)

Accounts Payable

1.5 m191.9 k

Cash From Operating Activities

746.1 k6.7 m5.9 m569.5 k

Purchases of PP&E

(97.4 k)(163.3 k)(143 k)(130.9 k)

Cash From Investing Activities

(5.1 m)(6 m)(2.3 m)(3.1 m)

Cash From Financing Activities

(9.2 m)(1.7 m)(5.2 m)(1.1 m)

Interest Paid

79.3 k28.4 k27.4 k21.9 k

Income Taxes Paid

(129.5 k)17.1 k52.2 k(8.4 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

709.5 k729.2 k26.5 k394.3 k121.7 k(268.6 k)(60.9 k)95.5 k(1.3 m)

Inventories

7 m6.1 m4.6 m4.8 m4.2 m4.1 m4.9 m5 m

Accounts Payable

4.2 m3.2 m3.4 m4.1 m4.1 m4.1 m3.7 m6.7 m7.3 m
USDY, 2017

Revenue/Employee

117.5 k

Financial Leverage

1.3 x

Cumberland Pharmaceuticals Market Value History

Traffic Overview of Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Company Life and Culture

You may also be interested in